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Introduction: Individuals with peripheral artery disease (PAD) often have reduced 
physical function and activity, which may increase the future risk of diabetes. 
Although diabetes is a risk factor of PAD, whether low ankle-brachial index (ABI) 
predates diabetes has not been studied.  
Methods: We examined the association of ABI with incident diabetes after accounting 
for potential confounders using Cox proportional hazards models in the ARIC Study. 
ABI was measured on a randomly selected leg in 12,247 black and white participants 
without prevalent diabetes at baseline (1987-1989). Incident diabetes cases were 
identified by glucose measurements (fasting ≥126 mg/dl or non-fasting ≥200 mg/dl) 
at subsequent three visits (1990-92, 1993-95, and 1996-98) and self-reported 
diagnosis or medication use at those visits or during annual phone interview through 
2011.  
Results: A total of 3,305 participants developed diabetes during a median of 21 years 
of follow-up. Participants with low (≤0.90) and borderline low (0.91-1.00) ABI had 
30-40% higher risk of future diabetes as compared to those with ABI of 1.10-1.20 in 
the demographically adjusted model. The associations were attenuated after further 
adjustment for other potential confounders but remained significant for ABI 0.90-1.00 
(HR=1.17, 95%CI 1.04-1.31) and marginally significant for ABI ≤0.90 (HR=1.19, 
0.99-1.43). Although the association was largely consistent across demographic and 
clinical subgroups, we observed borderline significant interaction for hypertension 
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status and fasting glucose, with a stronger association between ABI and diabetes risk 
in participants without hypertension and those with normal fasting compared to their 
counterparts. 
Conclusions: Low ABI was modestly but independently associated with increased 
risk of incident diabetes in the general population. Clinical attention should be paid to 
the glucose trajectory among people with low ABI. 
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Lower extremity peripheral arterial disease (PAD), typically defined by an ankle-brachial 
index (ABI) <0.9 [1], affects 8-10 million people in the United States [2]. PAD increases 
the risk of cardiovascular disease and reduces quality of life due to ischemic leg pain and 
intermittent claudication [1][3]-[5].  
Regardless of leg symptoms, patients with PAD experience functional decline and 
impairment [6]-[9], which can result in reduced level of physical activity [7][10][11]. 
Since physically inactivity is an important risk factor of diabetes [12]-[14], it is possible 
that low ABI is associated with the development of diabetes. In addition, delayed insulin 
delivery due to endothelial dysfunction, an early condition of atherosclerosis, is 
considered to contribute to the development of insulin resistance [17]-[20]. Shared 
pathophysiology between atherosclerosis and insulin resistance, such as the involvement 
of inflammation, may also contribute to the link of ABI to diabetes risk [21][22]. 
However, to the best of our knowledge, the association of ABI with future risk of diabetes 
has not yet been studied although the opposite direction of association (i.e., diabetes as a 
risk factor of PAD) is well-known [2][15][16]. Therefore, we aimed to investigate 
whether ABI is independently associated with incident diabetes in a community-based 






The ARIC Study is a community-based prospective cohort study of 15,792 individuals 
aged 45-64 years at baseline. Participants were recruited at baseline examination (visit 1) 
during 1987-1989 from four US communities: Forsyth County, North Carolina; Jackson, 
Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, Maryland [23]. 
The participants were invited for follow-up examinations every three years (visits 2 
[1990-1992], 3 [1993-1995], and 4 [1996-1998]). They also received annual telephone 
interview regarding their lifestyle and clinical conditions. The study was approved by the 
institutional review board at each field center, and informed consent was obtained from 
all participants. 
 Of 15,792 participants, we excluded 1,870 participants with prevalent diabetes 
(defined as self-reported diagnosis or treatment of diabetes, fasting blood glucose ≥126 
mg/dl or random blood glucose ≥200 mg/dl at baseline) and 148 participants with no 
information about diabetes status. We also excluded 44 non-white and non-black 
participants as well as those with missing information on ABI (n=476), any covariates at 
baseline (n=575), and incident diabetes during follow-up (n=432), leaving 12,247 
participants in our analysis.  
 
Exposure assessment 
ABI was defined as a ratio of systolic blood pressure of ankle to that of arm [24]. The 
ankle and brachial blood pressures were measured in a supine position by automated 
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oscillometric device Dinamap Model 1846 SX [25]. Ankle systolic blood pressure was 
measured four times in a randomly selected leg and the last non-missing value was used 
as numerator of ABI. Brachial systolic blood pressure was measured twice in the right 
arm and the first non-missing value was used as denominator of ABI [26].  
 
Outcome assessment 
The ascertainment of incident diabetes was based on two elements, self-reported 
physician diagnosis or treatment of diabetes during visits or phone interview through 
April 18, 2011 (interview-based definition) and fasting blood glucose ≥126 mg/dl,  
random blood glucose ≥200 mg/dl, or self-reported physician diagnosis or treatment of 
diabetes during visits 2 through 4 (visit-based definition), as previously done [27]. To 
maximize the statistical power, as the primary outcome, we combined these two 
definitions but also analyzed them separately as a secondary analysis. 
 
Covariates of interest 
Age, gender, race, parental history of diabetes, medical history of coronary heart disease 
(CHD) and stroke/transient ischemic attack (TIA), and smoking and alcohol drinking 
habits were self-reported at baseline. Medication use was assessed by self-report and 
examination of medication containers brought to the visit. Height, weight and sitting 
blood pressure were measured according to standardized protocols [28]. Hypertension 
was defined as a mean systolic blood pressure ≥140 mmHg or a mean diastolic blood 
pressure ≥90 mmHg, or use of antihypertensive drugs. Total cholesterol level, 
high-density lipoprotein cholesterol level and triglyceride level were measured using 
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enzymatic determination methods [29]. Glucose was measured using the 
hexokinase-glucose-6-phosphate dehydrogenase method [30].White blood cell count was 
measured by automated hematology analyzer [31]. Fibrinogen was measured using assay 
according to standard procedures [32]. Physical activity was assessed with the Baecke 
physical activity questionnaire, which recorded the duration, intensity and frequency of 
physical activity at work, in leisure time and during sports and produced an index score to 
represent level of physical activity [33].  
 
Statistical Analyses 
We categorized ABI into seven groups, ≤0.90, 0.91-1.00, 1.01-1.10, 1.11-1.20, 1.21-1.30, 
1.31-1.40 and >1.40, consistent with prior literature [4]. Baseline characteristics were 
compared across these groups, according to chi-square test and ANOVA, as appropriate. 
 To visualize potentially non-linear associations, we used Poisson regression models 
with ABI modeled using linear spline terms (knots at 0.9, 1.0, 1.1, 1.2, 1.3 and 1.4) and 
estimated incidence rates of diabetes according to ABI. We subsequently quantified the 
adjusted risk of incident diabetes according to the seven ABI categories using Cox 
proportional hazards models. ABI 1.11-1.20 was used as the reference group since this is 
the group that is commonly thought to have “normal” ABI and had the largest number of 
participants [34][35]. To evaluate the impact of potential confounding, we constructed 3 
models. Model 1 was adjusted for age, sex and race. Model 2 included all variables in 
Model 1 plus factors associated with atherosclerosis and diabetes, namely body mass 
index, total cholesterol, high-density lipoprotein cholesterol, and triglyceride, drinking 
and smoking status (current vs. never and former vs. never), systolic blood pressure, 
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hypertension medication use, history of coronary heart disease, stroke or transient 
ischemic attack (TIA), statin use, parental history of diabetes, white blood cell count, and 
physical activity index. Model 3 included all variables in Model 2 plus baseline fasting 
glucose. There was no major deviation from the proportional hazards assumption for ABI 
categories based on visual evaluation from log-log plot as well as from test on Schoenfeld 
residuals.  
 We tested for interaction and conducted subgroup analyses by age (≤ vs. >55 years), 
gender, race, smoking status (current vs. former/never), history of cardiovascular disease, 
history of stroke or TIA, hypertension status, baseline fasting glucose level (normal <100 
vs. impaired 100-125 mg/dl) and exertional leg pain status. Interaction was tested by 
incorporating a production term of ABI categories and subgroups in Cox models.  
 As to sensitivity analysis, we repeated the analysis in visit-based definition and 
interview-based definition of diabetes separately. We also explored the model which 
replaced white blood cell count with fibrinogen (an alternative inflammatory marker) in 
Model 2. Finally, we treated physical activity, a potential mediator of ABI-diabetes 
association, as a time-varying covariate using data assessed at visit 3 in addition to Model 
2 covariates.  
 All analyses were performed with Stata version 12.0. All p-values were two-sided, 
and p < 0.05 was considered statistically significant. 
 
Results 
The mean ABI of study population was 1.13 (SD 0.14). There were 455 individuals 
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(3.7%) with ABI ≤ 0.90 and 1,529 participants (12.5%) with borderline low ABI of 
0.91-1.00. There was no significant correlation between ABI and baseline fasting glucose 
(r=0.002, p-value=0.81). Baseline characteristics of study participants by ABI categories 
are shown in Table 1. As compared to participants with ABI 1.11-1.20 (reference group), 
those with lower ABI were more likely to be older, female, and blacks. They also had 
worse cardiovascular risk profiles relative to the reference group, including higher 
prevalence of current smokers, hypertension, and cardiovascular diseases (CHD and 
stroke/TIA), higher levels of body mass index, total cholesterol, triglyceride, white blood 
cell count, and fibrinogen, and lower level of physical activity. Participants with 
ABI>1.40, indicative of arterial stiffness [34], also had worse cardiovascular risk profiles 
as compared to those with ABI 1.11-1.20.  
 A total of 3,305 cases of incident diabetes were identified during a median of 21 
years of follow-up (incidence rate 16.8 [95%CI: 15.8-16.9] per 1,000 person-years). 
Figure 1 shows demographically adjusted incidence rates of diabetes according to ABI at 
baseline. The incidence rates of diabetes were lowest in ABI 1.10-1.30 and increased as 
ABI decreased below this range. The incidence rate of diabetes was similar or slightly 
higher in ABI >1.30 compared to ABI 1.10-1.30.  
 In a demographically adjusted Cox regression model with ABI 1.10-1.20 as the 
reference, low ABI categories were significantly associated with incident diabetes 
(hazard ratio [HR] 1.41 [95% CI 1.17-1.68] for ABI ≤0.90, 1.29 [1.15-1.45] for ABI 
0.91-1.00, and 1.10 [1.00-1.22] for ABI 1.01-1.10, Model 1 in Table 2). When we further 
adjusted for other potential confounders including white blood cell count and physical 
activity (Model 2 in Table 2), the associations for all low ABI categories remained 
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significant although it was borderline significant for ABI ≤0.90. The replacement of 
white blood cell count with fibrinogen did not make material difference (data not shown). 
After accounting for baseline fasting glucose (Model 3), the association remained 
marginally significant only in participants with ABI 0.91-1.00 (p-value=0.051). However, 
when we combined ABI≤0.90 and 0.91-1.00 groups, the association was statistically 
significant even in Model 3 (HR=1.12 [95% CI 1.01-1.24], p-value=0.034). For 
participants with ABI>1.40, we observed slight but non-significant increase in the risk of 
incident diabetes compared to those with ABI 1.11-1.20 in Models 1 and 3. The 
association was largely consistent when we analyzed interview-based cases and 
visit-based cases separately (Table S1 and Table S2). The model with physical activity as 
a time-varying covariate using visit 3 data showed similar results (data not shown). 
 To obtain reliable estimates in subgroup analyses, we dichotomized ABI at below 
and above 1.00. Given slight increase in the risk of diabetes in some models, those with 
ABI >1.40 were excluded from this analysis. Overall, no significant interaction was 
observed between ABI and potential modifiers tested (Table 3). However, we observed 
borderline significant difference in the association of ABI with diabetes in participants 
with vs. without hypertension (HR 1.20 [95%CI 1.07-1.35] vs. 1.01 [0.88-1.15], p-value 
for interaction = 0.054) and those with normal vs. impaired fasting glucose (HR 1.20 
[95% CI 1.04-1.39] vs.1.01 [0.90-1.14], p-value for interaction = 0.072). The higher risk 
of diabetes was confirmed for both ABI categories of ≤0.90 and 0.91-1.00 in participants 





This study, to our knowledge, is the first study to examine the association between ABI 
and the future risk of diabetes. We found that low ABI (≤1.0) was associated with a 
moderately increased risk of diabetes. The association was independent of other 
atherosclerotic cardiovascular diseases, physical activity, and other potential confounders. 
We did not observe any significantly different results in demographic and clinical 
subgroups. However, the association of ABI with diabetes risk was stronger in 
participants without hypertension and those with normal fasting compared to their 
counterparts, with a borderline significant interactions. 
 ABI is a marker of systematic atherosclerosis [36], and participants with low ABI 
indeed had worse cardiovascular risk profiles in our study. Several traditional 
cardiovascular risk factors such as hypertension, smoking, and dyslipidemia are known to 
be related to high risk of developing diabetes [37]-[41]. Thus, we rigorously adjusted for 
these traditional risk factors but still observed significant associations between ABI and 
risk of diabetes. Although chronic inflammation can be a common ground for 
development of both atherosclerosis and diabetes [21][22][42][43], our results were not 
altered with adjustment for white blood cell count or fibrinogen. Although ABI may be 
associated with diabetes through its impact on physical activity, the adjustment for 
physical activity as both time-fixed and time-varying covariates did not meaningfully 
attenuate the association. Nevertheless, we need to keep in mind that physical activity 
was self-reported in our study, which may misclassify true physical activity level [44]. 
 We found that the association between low ABI (≤1.00) and risk of diabetes tended 
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to be stronger in participants without hypertension and those with normal fasting glucose 
as compared to their counterparts, with borderline significant interaction. We are not 
necessarily sure about mechanisms behind these suggestive interactions, but there may be 
a few potential explanations. Many of those with hypertension were treated with 
antihypertensive medications (72%), which might confound the ABI-diabetes association. 
Indeed, renin-angiotensin system inhibitors are reported to reduce the risk of diabetes 
[45][46], whereas diuretics and beta blockers may contribute to increased risk of 
developing diabetes [47][48]. People with impaired fasting glucose are known to already 
have reduced insulin sensitivity and β cell dysfunction [49] and thus already at high risk 
of diabetes. For these individuals, a mild single predictor such as ABI may not 
considerably contribute to discriminating their diabetes risk. Another possible explanation 
is that the performance of ABI as a diagnostic tool for PAD might be inferior in those 
with hypertension and impaired fasting glucose than in their counterparts. For example, 
low sensitivity of ABI to detect PAD (41%) has been reported in patients with diabetes 
due to high prevalence of arterial stiffness [34], and persons with impaired fasting 
glucose also were known to have higher prevalence of arterial stiffness compared to those 
with normal glucose [50].  
Previous studies showed that people with PAD were at high risk of other 
cardiovascular diseases, such as coronary heart disease, stroke and heart failure 
[4][51]-[54]. In addition, these individuals are known to have increased risk of leg 
amputation and reduced quality of life (e.g., low physical functioning, bodily pain, and 
reduced vitality) [5][55]-[59]. Our study demonstrates elevated risk of future diabetes 
among persons with low ABI independent of other cardiovascular diseases and risk 
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factors. ABI is able to identify subclinical atherosclerosis, which may encourage early 
initiation or better compliance of cardiovascular risk factor control [36][59]. In addition 
to risk factor management, our results suggest that attentions should also be given to 
glucose trajectory in people with low or borderline low ABI even when their fasting 
glucose is within the normal range.  
 Our study has several limitations. First, ABI was measured once for a randomly 
selected leg at baseline. The prevalence of low ABI may be underestimated as a result of 
missing low ABI in the opposite leg in some participants. Second, there were 15 years of 
follow-up where incident diabetes cases were solely based on self-report (interview-based 
definition). However, as aforementioned, the association was largely consistent for 
visit-based and interview-based diabetes. Third, our study participants were 45-64 years 
old at baseline, and thus the generalization of our results to adults in other age ranges 
should be done with caution. Finally, like other observational studies, residual 
confounding cannot be denied. 
 In conclusion, low ABI (≤1.00) was modestly but independently associated with 
increased risk of future diabetes in community-based middle-aged populations. The 
association was more evident in people with fasting glucose and blood pressure in the 
normal range. Although future studies are needed to confirm our findings and investigate 
potential mechanisms, our study suggests that attentions should be given to glucose 
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Table 1 Baseline Characteristics of Participants without Prevalent Diabetes by ABI Categories 
Characteristics ABI≤0.90 0.91-1.00 1.01-1.10 1.11-1.20 1.21-1.30 1.31-1.40 ABI>1.40 
N (%) 455 (3.7) 1,529 (12.5) 2,894 (23.6) 3,633 (29.7) 2,509 (20.5) 924 (7.5) 303 (2.5) 
Age, mean(SD),years* 54.9 (5.9) 53.7 (5.8) 53.4 (5.6) 53.9 (5.8) 53.9 (5.6) 54.6 (5.7) 55.1 (5.7) 
Female, No. (%) * 321 (70.6) 1116 (73.0) 1867 (64.5) 1903 (52.4) 1104 (44.0) 373 (40.4) 125 (41.3) 
Black, No. (%) * 121 (26.6) 357 (23.4) 700 (24.2) 867 (23.9) 542 (21.6) 177 (19.2) 47 (15.5) 
BMI,  mean(SD), kg/m2 * 27.7 (6.0) 27.7 (5.8) 27.1 (5.2) 27.0 (4.7) 27.0 (4.6) 27.4 (4.8) 28.3 (5.5) 
Current Drinker, No. (%)* 244 (53.6) 874 (57.2) 1698 (58.7) 2189 (60.3) 1525 (60.8) 550 (59.5) 163 (53.8) 
Current Smoker, No. (%)* 167 (36.7) 440 (28.8) 798 (27.6) 855 (23.5) 602 (24.0) 195 (21.1) 63 (20.8) 
Arm SBP, mean(SD),mmHg* 123.0 (19.7) 121.0 (19.2) 120.3 (18.8) 119.7 (17.5) 118.2 (16.6) 118.0 (15.8) 117.6 (15.3) 
Hypertension Medication, No. (%)* 169 (37.1) 449 (29.4) 810 (28.0) 932 (25.7) 587 (23.4) 221 (23.9) 95 (31.4) 
Prevalent CHD, No. (%)* 30 (6.6) 68 (4.5) 103 (3.6) 137 (3.8) 103 (4.1) 38 (4.1) 20 (6.6) 
Stroke or TIAa, No. (%)* 33 (7.3) 68 (4.5) 123 (4.3) 151 (4.2) 99 (4.0) 26 (2.8) 15 (5.0) 
Total Cholesterol, mean(SD),mg/dl* 223.3 (43.3) 216.0 (40.0) 215.4 (42.2) 213.5 (41.0) 211.9 (39.4) 211.3 (39.8) 211.2 (41.1) 
HDL,mean(SD),mg/dl* 53.3 (17.4) 54.2 (17.6) 54.3 (17.5) 52.3 (17.1) 51.2 (16.8) 50.3 (16.3) 49.4 (15.3) 
Triglyceride,median(IQR),mg/dl * 113 (80-159) 105 (77-146) 103 (75-145) 106 (77-150) 108 (77-151) 106 (76-150.5) 112 (80-160) 
Statin Use, No. (%) 5 (1.1) 13 (0.9) 16 (0.6) 12 (0.3) 9 (0.4) 5 (0.5) 2 (0.7) 
Fasting Glucose,mean(SD),mg/dl 99.2 (9.5) 98.6 (9.3) 98.5 (9.4) 98.5 (9.1) 99.0 (9.2) 98.7 (9.0) 98.4 (9.0) 
Parental History of Diabetes, No. (%) 104 (22.9) 363 (23.7) 633 (21.9) 809 (22.3) 580 (23.1) 190 (20.6) 76 (25.1) 
White Blood Cell Count,  
median(IQR), 103 * 
6.3 (5.1-7.5) 5.9 (4.9-7.2) 5.8 (4.8-7.0) 5.6 (4.7-6.9) 5.6 (4.7-6.9) 5.7 (4.7-6.8) 5.6 (4.7-6.9) 
Fibrinogen, median(IQR),mg/dl * 314 (277-362) 295 (261-342) 295 (260-336) 288 (255-327) 285 (255-324) 286 (254-323) 294 (261-333) 
Physical Activity Index,  mean(SD)* 6.7 (1.5) 6.9 (1.5) 7.0 (1.4) 7.1 (1.4) 7.2 (1.4) 7.2 (1.4) 7.2 (1.5) 
Abbreviations: ABI, ankle-brachial index; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TIA, transient ischemic attack; CHD, coronary heart 
disease; HDL, high density cholesterol. 




Table 2 Hazard Ratios of Diabetes in Different ABI Categories 
 
ABI ≤0.90 0.91-1.00 1.01-1.10 1.11-1.20 1.21-1.30 1.31-1.40 >1.40 
N 12,247 455 1,529 2,894 3,633 2,509 924 303 
Number of 
events 
3,305 137 457 781 927 668 249 86 
Model 1 
HR 1.41 1.29 1.10 1.00 1.06 1.07 1.16 
95%CI 1.17-1.68 1.15-1.45 1.00-1.22 -- 0.96-1.17 0.93-1.23 0.93-1.45 
Model 2 
HR 1.19 1.17 1.10  1.00 1.08 1.10 1.01 
95%CI 0.99-1.43 1.04-1.31 1.00-1.21 -- 0.98-1.20 0.96-1.27 0.81-1.27 
Model 3 
HR 1.12 1.12 1.08  1.00 1.06 1.09 1.12 
95%CI 0.94-1.34 0.99-1.26 0.98-1.18 -- 0.96-1.17 0.94-1.25 0.90-1.40 
Model 1: adjusted for age, gender and race; Model 2: adjusted for age, gender, race, current and former drinking, current and 
former smoking, BMI, SBP, hypertension medication, HDL, total cholesterol, log(triglyceride), prevalent CHD, stroke or TIA, 
statin use, parental history of diabetes, log(white blood cell count) and Baecke physical activity index; Model 3: adjusted for 





Table 3 Hazard Ratios of Diabetes in Different Subgroups 
Subgroup 
HR and 95% CI  





HR and 95% CI  






Stroke or TIA   
Male (5,260) 1.19 (1.01-1.40)  No (11,444) 1.09 (0.99-1.19)  
Female (6,684) 1.07(0.96-1.19) 0.274 Yes (500) 1.43 (1.00-2.05) 0.141 
Race   Hypertension   
White (9,180) 1.13 (1.02-1.26)  No (8,923) 1.20 (1.07-1.35)  
Black (2,764) 1.05 (0.89-1.23) 0.423 Yes (3,622) 1.01 (0.88-1.15) 0.054 
Age   
Family history of 
diabetes 
  
≤55 (7,193) 1.06(0.94-1.16)  No (9,625) 1.05 (0.94-1.18)  







No (8,887) 1.09 (0.98-1.21)  No (6,895) 1.20 (1.04-1.39)  
Yes(3,057) 1.17 (0.99-1.38) 0.480 Yes (5,049) 1.02 (0.90-1.14) 0.072 
Prevalent CHD   
Leg Pain While 
Walking 
  
No (11,465) 1.11 (1.02-1.22)  No (9,606) 1.10 (0.99-1.23)  
Yes (479) 0.91 (0.59-1.42) 0.383 Yes (2,338) 1.10 (0.92-1.30) 0.958 
N=11944. Excluded ABI>1.4 and adjusted for age, gender, race, current and former drinking, current and former 
smoking, BMI, SBP, hypertension medication, HDL, total cholesterol, log(triglyceride), prevalent CHD, stroke or TIA, 





Figure 1 Demographically Adjusted Incidence Rates of Diabetes according to ABI and Distribution of ABI. 





Table 4 Hazard Ratios of Interview-based Definition of Diabetes in Different ABI Categories 
 
ABI ≤0.90 0.91-1.00 1.01-1.10 1.11-1.20 1.21-1.30 1.31-1.40 >1.40 
N 11,292 390 1,397 2,668 3,373 2,320 861 283 
Number of 
events 
2,959 118 414 698 841 596 217 75 
Model 1 
HR 1.39 1.29 1. 08 1.00 1.05 1.02 1.12 
95%CI 1.15-1.69 1.14-1.45 0.98-1.20 -- 0.94-1.16 0.88-1.18 0.88-1.42 
Model 2 
HR 1.21 1.16 1.08 1.00 1.06 1.04 0.98 
95%CI 1.00-1.47 1.03-1.30 0.97-1.19 -- 0.95-1.18 0.89-1.20 0.77-1.24 
Model 3 
HR 1.16 1.12 1.05 1.00 1.04 1.03 1.07 
95%CI 0.96-1.41 0.99-1.26 0.95-1.16 -- 0.94-1.16 0.88-1.19 0.84-1.35 
Model 1: adjusted for age, gender and race; Model 2: adjusted for age, gender, race, current and former drinking, current and former 
smoking, BMI, SBP, hypertension medication, HDL, total cholesterol, log(triglyceride), prevalent CHD, stroke or TIA, statin use, 
parental history of diabetes, log(white blood cell count) and Baecke physical activity index; Model 3: adjusted for baseline fasting 




Table 5 Hazard Ratios of Visit-based Definition of Diabetes in Different ABI Categories 
 
ABI ≤0.90 0.91-1.00 1.01-1.10 1.11-1.20 1.21-1.30 1.31-1.40 >1.40 
N 11,858 432 1,481 2,798 3,525 2,441 889 292 
Number of 
events 
1,385 59 185 332 378 287 110 34 
Model 1 
HR 1.51 1.26 1. 13 1.00 1.12 1.12 1.02 
95%CI 1.15-1.99 1.05-1.50 0.98-1.31 -- 0.96-1.31 0.90-1.38 0.72-1.45 
Model 2 
HR 1.23 1.15 1.14 1.00 1.18 1.16 1.01 
95%CI 0.94-1.63 0.96-1.38 0.98-1.32 -- 1.01-1.37 0.93-1.43 0.71-1.44 
Model 3 
HR 1.26 1.05 1.02 1.00 1.06 1.08 0.99 
95%CI 0.96-1.67 0.88-1.26 0.88-1.19 -- 0.91-1.24 0.87-1.33 0.70-1.42 
Model 1: adjusted for age, gender and race; Model 2: adjusted for age, gender, race, current and former drinking, current and former 
smoking, BMI, SBP, hypertension medication, HDL, total cholesterol, log(triglyceride), prevalent CHD, stroke or TIA, statin use, 
parental history of diabetes, log(white blood cell count) and Baecke physical activity index; Model 3: adjusted for baseline fasting 




Table 6 Hazard Ratios of Diabetes in Baseline Fasting Glucose<100 mg/dl and 100-125 mg/dl population 
 
ABI ≤0.90 0.91-1.00 1.01-1.10 1.11-1.20 1.21-1.30 1.31-1.40 >1.40 
N 7,080 257 880 1,707 2,093 1,419 539 185 
Number of 
events 
1,242 53 178 297 349 241 88 36 
<100 mg/dl 
HR 1.33 1.27 1.06 1.00 1.06 1.03 1.03 
95%CI 0.99-1.79 1.06-1.53 0.90-1.23 -- 0.90-1.25 0.82-1.31 0.73-1.45 
N 5,167 198 649 1,187 1,540 1,090 385 118 
Number of 
events 
2,063 84 279 484 578 427 161 50 
100-125 
mg/dl  
HR 1.09 1.07 1.13 1.00 1.09 1.17 1.14 
95%CI 0.87-1.38 0.93-1.24 1.00-1.28 -- 0.96-1.23 0.98-1.40 0.85-1.53 
Adjusted for age, gender, race, current and former drinking, current and former smoking, BMI, SBP, hypertension medication, 
HDL, total cholesterol, log(triglyceride), prevalent CHD, stroke or TIA, statin use, parental history of diabetes, log(white blood 







Table 7 Hazard Ratios of Diabetes in Study Participants with and without Hypertension at Baseline 
 
ABI ≤0.90 0.91-1.00 1.01-1.10 1.11-1.20 1.21-1.30 1.31-1.40 >1.40 
N 8,539 265 1,023 1,961 2,556 1,837 680 217 
Number of 
events 
1,954 77 259 423 568 425 154 48 
No 
hypertension 
HR 1.41 1.17 1.00 1.00 1.05 1.06 0.89 
95%CI 1.11-1.79 1.00-1.35 0.88-1.14 -- 0.92-1.19 0.88-1.26 0.66-1.19 
N 3,708 190 506 933 1,077 672 244 86 
Number of 
events 
1,351 60 198 358 359 243 95 38 
hypertension 
HR 1.02 1.19 1.26 1.00 1.13 1.17 1.25 
95%CI 0.78-1.35 0.99-1.41 1.09-1.46 -- 0.96-1.33 0.93-1.47 0.89-1.75 
Adjusted for age, gender, race, current and former drinking, current and former smoking, BMI, HDL, total cholesterol, 
log(triglyceride), prevalent CHD, stroke or TIA, statin use, parental history of diabetes, log(white blood cell count) and Baecke 
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